Praziquantel: a new schistosomicide against Schistosoma haematobium.
The effectiveness of the new schistosomicide praziquantel was assessed in African schoolchildren infected with Schistosoma haematobium. They were stratified according to the severity of their infection and were then randomly allocated to treatment with two single-dose regimens (30 and 40 mg/kg) and a split regimen of two doses of 20 mg/kg given four hours apart. All three regimens were highly effective and produced few side effects. Children who initially had very high pretreatment egg loads showed a poorer therapeutic response at all dose levels, and further investigations are necessary to find the optimum dose. Because of its effectiveness in a single dose and lack of toxicity, praziquantel may prove to be the ideal schistosomicide.
D000293:Adolescent; D002648:Child; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D010270:Parasite Egg Count; D011223:Praziquantel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012548:Schistosoma haematobium; D012552:Schistosomiasis / Q000188:drug therapy*; D012556:Schistosomicides
D007546:Isoquinolines; D012556:Schistosomicides; D011223:Praziquantel